SCHEMBL23213840

SCHEMBL23213840

COCCOc1cc(NC(=O)O)cc(Cl)c1C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
RECQL P46063 1/20 0.42
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.38
KMO O15229 1/20 0.38
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
TDP1 Q9NUW8 2/20 0.38
HRH3 Q9Y5N1 1/20 0.37
GAA P10253 2/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
MCL1 Q07820 1/20 0.37
RORC P51449 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23239901 0.84 RECQL (0.38) MAPTRECQLKDM4EALDH1A1L3MBTL1
SCHEMBL29716399 0.84 RECQL (0.38) MAPTRECQLKDM4EALDH1A1L3MBTL1
SCHEMBL23239902 0.84 POLB (0.57) MAPTKDM4EALDH1A1L3MBTL1HPGD
SCHEMBL29716405 0.84 POLB (0.57) MAPTKDM4EALDH1A1L3MBTL1HPGD
SCHEMBL23213363 0.83 KDM4E (0.47) KDM4EALDH1A1TDP1HRH3GAA
SCHEMBL23213226 0.82 ALDH1A1 (0.53) MAPTKDM4EALDH1A1THRATHRB
SCHEMBL23213568 0.79 PLAU (0.45) KDM4EALDH1A1L3MBTL1HPGDHTT
SCHEMBL23213447 0.78 S1PR4 (0.42) MAPTRECQLKDM4EALDH1A1L3MBTL1
SCHEMBL29795901 0.78 S1PR4 (0.42) MAPTRECQLKDM4EALDH1A1L3MBTL1
SCHEMBL23213520 0.76 ALDH1A1 (0.54) MAPTKDM4EALDH1A1HTTKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 MAPT 4671/4885RECQL 502/4885KDM4E 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.